Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Manuel Otero-Santiago"'
Autor:
Alana Aragón-Herrera, Sandra Moraña-Fernández, Manuel Otero-Santiago, Laura Anido-Varela, Manuel Campos-Toimil, Javier García-Seara, Ana Román, José Seijas, Lucía García-Caballero, Javier Rodríguez, Estefanía Tarazón, Esther Roselló-Lletí, Manuel Portolés, Ricardo Lage, Oreste Gualillo, José Ramón González-Juanatey, Sandra Feijóo-Bandín, Francisca Lago
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 161, Iss , Pp 114535- (2023)
The pharmacological inhibition of sodium-glucose cotransporter 2 (SGLT2) has emerged as a treatment for patients with type 2 diabetes mellitus (T2DM), cardiovascular disease and/or other metabolic disturbances, although some of the mechanisms implica
Externí odkaz:
https://doaj.org/article/25810c314aa64857b4150a43206f7eb0
Autor:
Alana Aragón-Herrera, Manuel Otero-Santiago, Laura Anido-Varela, Sandra Moraña-Fernández, Manuel Campos-Toimil, Tomás García-Caballero, Luis Barral, Estefanía Tarazón, Esther Roselló-Lletí, Manuel Portolés, Oreste Gualillo, Isabel Moscoso, Ricardo Lage, José Ramón González-Juanatey, Sandra Feijóo-Bandín, Francisca Lago
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in patients with Type 2 Diabetes Mellitus (T2DM)) trial evidenced the potential of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of patients with diabetes a
Externí odkaz:
https://doaj.org/article/0582b3904297450b8681e7c0da82b354
Autor:
Sandra Feijóo-Bandín, Alana Aragón-Herrera, Manuel Otero-Santiago, Laura Anido-Varela, Sandra Moraña-Fernández, Estefanía Tarazón, Esther Roselló-Lletí, Manuel Portolés, Oreste Gualillo, José Ramón González-Juanatey, Francisca Lago
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 10, p 5634 (2022)
Sodium-glucose co-transporter 2 inhibitors, also known as gliflozins, were developed as a novel class of anti-diabetic agents that promote glycosuria through the prevention of glucose reabsorption in the proximal tubule by sodium-glucose co-transport
Externí odkaz:
https://doaj.org/article/c7e3bfbb9d714e2db1a5f52e4163d6b8
Autor:
Alana Aragón-Herrera, Manuel Otero-Santiago, Laura Anido-Varela, Sandra Moraña-Fernández, Manuel Campos-Toimil, Tomás García-Caballero, Luis Barral, Estefanía Tarazón, Esther Roselló-Lletí, Manuel Portolés, Oreste Gualillo, Isabel Moscoso, Ricardo Lage, José Ramón González-Juanatey, Sandra Feijóo-Bandín, Francisca Lago
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
RUC. Repositorio da Universidade da Coruña
instname
RUC. Repositorio da Universidade da Coruña
instname
[Abstract] The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in patients with Type 2 Diabetes Mellitus (T2DM)) trial evidenced the potential of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of patients with
Autor:
Santiago Rodríguez-Segade, Manuel Portolés, Oreste Gualillo, Alana Aragón-Herrera, Estefanía Tarazón, Javier Maseda Rodríguez, F. Lago, José Ramón González-Juanatey, Manuel Otero Santiago, Esther Roselló-Lletí, Sandra Feijóo-Bandín, Manuel Campos-Toimil, José Gil-Longo, Thiago de Melo Costa Pereira, Luis Barral, Tomás García-Caballero
Publikováno v:
Biochemical Pharmacology. 170:113677
The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in patients with Type 2 Diabetes Mellitus (T2DM)) trial made evident the potentiality of pharmacological sodium-glucose cotransporter 2 (SGLT2) inhibition for treating patients w
Autor:
Rocío Ferreiro-Iglesias, Alfonso Javier Benítez Estévez, J.E. Dominguez-Muñoz, Aurelio Lorenzo González, Manuel Otero Santiago, Manuel Barreiro-de Acosta, Carmen Alonso de la Peña
Publikováno v:
Journal of clinical gastroenterology. 50(2)
Predicting relapse in Inflammatory Bowel Disease (IBD) could allow for early changes of treatment. Close monitoring of fecal calprotectin (FC) could be useful to predict relapse in IBD. Aim of the study was to evaluate the predictive value of a rapid